The purpose of this study is to provide patients with AMTAGVI (lifileucel) that is Out of Specification for Commercial Release.
   
In this study, AMTAGVI will be given intravenously (meaning through a needle in the vein directly into the blood).

Participation is expected to last up to 24 months.

The overall objective of our proposal is to gain a comprehensive understanding of the quality of online information about prostate cancer and to investigate the link between consumption of online information with attitudes toward PSA screening to help overcome barriers and reduce disparities in prostate cancer screening.
   
Aim 1: Evaluate the quality and readability of the online information regarding prostate cancer screening utilizing validated questionnaires and our manual and digital assessment tools.
   

Posttraumatic stress disorder (PTSD) occurs in approximately 7% of adults in the general population. PTSD greatly impacts quality of life and often co-occurs with other conditions, such as chronic pain. Individuals with co-morbid PTSD and chronic pain demonstrate higher PTSD symptoms and pain (as well as greater anxiety, depression, disability, and opioid use) compared to those with only one of those conditions.

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapse) or may not get better (refractory) with treatment. This is a study to determine the safety, efficacy, and pharmacokinetics of Etentamig in adult participants with MM.
   

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD.

Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD).

This clinical trial is for men and women with newly diagnosed multiple myeloma who are not considered a candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT).
   
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).
   

This clinical trial is for adults who have been diagnosed with non-small cell lung cancer (NSCLC).

This clinical trial is for adults who have relapsed or refractory multiple myeloma (either their disease has come back, or it is no longer responding to their current treatment) and standard therapies available to treat their disease may have limited effectiveness.
   

The purpose of this study is to evaluate the safety and effectiveness of the Elevate System for patients needing non-emergent percutaneous coronary intervention (PCI).

The Elevate System is an investigational heart pump device, which means it has not been approved by the U.S. Food and Drug Administration (FDA). It is being compared with an already approved heart pump device called the Impella System. The Impella System is approved for patients having HR-PCI.

The purpose of this study is to evaluate the safety and efficacy of percutaneous endovascular catheter-facilitated intramyocardial delivery of XC001 in treating refractory angina compared to standard treatment.